Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in ...

Novocure (NASDAQ:NVCR) shares rose 6% after market on announcing U.S. FDA approval for Optune Lua for the treatment of adult ...

There are currently no curative therapeutic options for GBM and treatment includes maximal surgical resection, radiation therapy (RT ... that alternating electric fields in the intermediate ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

Novocure stock rocketed late Tuesday after the FDA signed off on its treatment for patients with metastatic lung cancer.

Optune Lua is a wearable device for which tumor-treating fields (TTFields) inhibit the proliferation and metastasis of lung ...

Novocure has launched Optune ... TTFields. The TTFields therapy consists of low-intensity, alternating electric fields that slow and reverse tumor growth by interfering with the mitotic process ...

H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...

ROOT, Switzerland, October 01, 2024--(BUSINESS WIRE)--Novocure (NASDAQ ... and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved ...

Novocure GmbH secured U.S. FDA approval for Optune Lua, a wearable device that delivers alternating electric fields or tumor treating fields that kill cancer cells. Indicated for use with PD-1/PD-L1 ...